WO2001002431A1 - Adenovirus recombinant - Google Patents

Adenovirus recombinant Download PDF

Info

Publication number
WO2001002431A1
WO2001002431A1 PCT/SE2000/001390 SE0001390W WO0102431A1 WO 2001002431 A1 WO2001002431 A1 WO 2001002431A1 SE 0001390 W SE0001390 W SE 0001390W WO 0102431 A1 WO0102431 A1 WO 0102431A1
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
fiber
seq
adenovirus according
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2000/001390
Other languages
English (en)
Inventor
Leif Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Got-A-Gene AB
Original Assignee
Got-A-Gene AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902601A external-priority patent/SE9902601D0/xx
Application filed by Got-A-Gene AB filed Critical Got-A-Gene AB
Priority to CA002378324A priority Critical patent/CA2378324A1/fr
Priority to EP00946680A priority patent/EP1196435A1/fr
Priority to AU60401/00A priority patent/AU763733B2/en
Priority to KR1020027000132A priority patent/KR20020092886A/ko
Priority to JP2001508218A priority patent/JP2003531568A/ja
Publication of WO2001002431A1 publication Critical patent/WO2001002431A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Definitions

  • the present invention relates to new recombinant - adenovirus with changed tropism. More particularly the recombinant adenovirus has been constructed by removing the native knob structure and replacing it with a new cell binding ligand and an external trimerisation motif. The invention also relates to the new adenovirus for treatment of human diseases. Also included is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome.
  • Clinical gene therapy was introduced in 1989. The aim at that time was to correct a gene defect in the immune system through the in vitro introduction of a healthy gene into the defect cells of the patient and transfusion of the treated cells back to the patient. Since that time, the possible indications for gene therapy have increased dramatically.
  • gene therapy to treat e.g. diseases of the blood vessels, cancer, inflammatory diseases and infectious diseases such as HIV can be envisaged.
  • gene therapy is not a useful method in human medicine.
  • gene therapy demands the packaging of the genes to be delivered into gene-carriers, or vectors, which can be injected into patients and which will target the genes only to the intended cells.
  • vectors have so far not been available .
  • Adenoviruses are DNA viruses without an envelope, shaped as regular icosahedrons with a diameter of 60-85 nm. Cell-binding takes place through fiber proteins, anchored to the virion at the corners of the icosahedron. The fiber protein is not necessary for assembly and release of intact virions. Assembly of virions take place in the nucleus of infected cells.
  • the fiber protein which is a homotrimer of a fiber polypeptide, contains three functionally different parts: an N-terminal tail anchoring the fiber non-covalently to the penton base in the virion and which furthermore contains the nuclear-localization signal; an approximate 15 amino acid fiber shaft motif which is repeated six times in Ad3 and 22 times in Ad2 and Ad5 (Chrobozek J, Ruigrok RWH and Cusack S: Adenovirus Fiber, Current
  • Each shaft repeat has two three-amino acid regions which form ⁇ - sheets and two amino acid regions which constitute the turns of the native extended fiber shaft.
  • the crystal structure of the trimerised, cell-binding domain has been determined and shows a unique topology different from other anti-parallel ⁇ -sandwiches (Di Xia, Henry LJ,
  • Gerard RD and Deisenhofer J Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution, Structure 2: 1259-1270, 1994.) . Binding of the fiber to the penton base of the virion can take place also in a cell-free system, i.e. the fiber can bind to fiberless virions (Boudin M-L and Boulanger P: Assembly of Adenovirus Penton Base and Fiber, Virology, 116: 589-604, 1982).
  • the FLAG tetra-amino acid motif By introducing the FLAG tetra-amino acid motif into the Ad penton, it has .been shown possible to target Ad to cells normally not infected by Ad. This was done by targeting with bi-specific antibodies where one specificity was directed against the FLAG peptide and the other against the new target cell (Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM and Kovesdi I: Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies. J. Virol . , 70 : 6831 - 6838 , 1996. ) .
  • Another object of the invention is the recombinant adenovirus for treatment of human diseases.
  • a further object of the invention is a method for rescuing of recombinant adenovirus fibers into the adnovirus genome.
  • the structural modification has been performed by DNA technology at the gene level or by chemical or immunological means at the virus level .
  • adenovirus as identified above, is used for the treatment of human diseases, either in vivo or by in vitro methods.
  • a further aspect of the invention is a method for rescuing of recombinant adenovirus fibers into the adenovirus genome comprising the following steps:
  • Sequence listing containing an Xhol site d) ligation of recombinant fiber between Ndel and Xhol of construct under c) above; e) re-introduction of construct under d) above into the 9 kb fragment cut with Nhel using homologous recombination in E. coli; f) isolation of the recombinant 9 kb fragment under e) and re-creation of the adenovirus genome by joining 9 kb fragment to the 27 kb fragment from the beginning of the genome to the Spel site by Cosmid cloning.
  • Fig. 1 Summary of modifications to native fiber carried out in the invention.
  • Fig. 2 Recombinant adenovirus fibers.
  • Fig. 3 Method for rescuing of recombinant fiber genes into the Ad genome .
  • Fig. 4a Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures.
  • Fig. 4b Recombinant fibers rescued into Ad genomes which are capable of giving CPE/plaques on transfected cells and in secondary cultures .
  • re-targeting of Ad is achieved through the introduction of a new cell-binding ligand into the fiber (Fig. 1) .
  • a new cell-binding ligand e.g. a monoclonal antibody or a fragment thereof whether as a single chain fragment or Fab, a T cell receptor or a fragment thereof, an integrin binding peptide such as RGD or a growth factor such as Epidermal Growth Factor.
  • Ligands which so far have been applied include Epidermal Growth Factor (EGF) , the amino acid motif RGD, a single chain fragment of a cloned T-cell receptor (scTCR) reactive with MAGE-1 peptides associated with HIA-A1 (vd Bruggen P, Traversaari C, Chomez P, Lurquin D, De Plaen E, vd Eynde B, Knuth A and Boon T: A Gene encoding an EGF-derived neurotrophic factor (vd Bruggen P, Traversaari C, Chomez P, Lurquin D, De Plaen E, vd Eynde B, Knuth A and Boon T: A Gene encoding an
  • Ad vectors can be made replication competent or incompetent for permissive cells.
  • replication competent Ad has the potential advantage that it can replicate and spread within the tumor (Miller R and Curiel DT: Towards the use of replicative adenoviral vectors for cancer gene therapy, Gene Therapy 3: 557- 559) . This may theoretically result in an increase of the chosen effector mechanism over that obtainable with replication incompetent vectors.
  • infectious virus may contribute to an anti tumor effect by cytopathogenic effects in infected cells as well as by evoking an anti viral immune response which may harm infected cells.
  • the aim has been to develop a universal method for the construction of functional Ad fibers with changed binding-specificity to make possible the construction of re-targeted Ad.
  • the adenovirus fiber peptide carries several biological functions which are necessary to retain in order to produce active virus particles.
  • the following fiber features are deemed to be of key importance in the construction of functional recombinant fiber peptides:
  • recombinant fibers are constructed and evaluated in vitro after cell-free expression in a coupled transcription/translation system. Analysis by SDS-PAGE and autoradiography is performed to reveal the presence of an open reading frame and give information on the size of the translated product.
  • next stage recombinant fibers are cloned into Baculovirus and expressed in insect cells allowing for functional studies of the fibers. Such studies include ability to form trimers as evaluated by immunostaining with monoclonal antibody 2A6.36 which has been shown to react only with trimerised fibers (Shin Hong J and Engler JA: The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal, Virology 185: 758-767,
  • Recombinant fibers are constructed using, methodology based on PCR (Clackson T, G ⁇ ssow D and Jones PT: General application of PCR to gene cloning and manipulation, in PCR, A Practical Approach, Eds McPherson MJ, Quirke P and Taylor GR, IRL Press, Oxford, p 187, 1992), e.g. PCR- ligation-PCR (Alvaro Ali S, Steinkasserer A: PCR- ligation-PCR Mutagenesis: A Protocol for Creating Gene Fusions and Mutations, BioTechniqrues 18: 746-750, 1995) and splicing by overlap extension (SOE) (Horton RM and
  • Pease LR Recombination and mutagenesis of DNA sequences using PCR, in McPherson MJ (ed) , Directed Mutagenesis, IRL Press 1991, p 217.) . Cloning is performed according to standard methods. Recombinant fibers are sequenced using Perkin Elmer ABI Prism and are expressed in mammalian cells and in insect cells and stained with monoclonal antibodies specific for fiber tail, trimeric fiber and the new cell-binding ligand. The following parameters are evaluated after immunostaining :
  • Fiber peptides are made where the knob is replaced with an external trimerisation motif which is introduced after the TLWT motif which ends the shaft portion of the fiber.
  • the purpose behind the introduction of an external trimerisation motif is two-fold: a) to remove the knob containing the native trimerisation signal but also the cell-binding part of the fiber, and b) simultaneously to supply the necessary trimerisation signal.
  • trimerisation motifs are synthesized, cloned and sequenced in the project.
  • a new cellbinding ligand is introduced into the fiber in addition to the external trimerisation amino acid motif.
  • Type A where the trimerisation motif is fused to the fiber gene downstream of the fiber shaft after the TL T motif which constitutes the four first amino acids of the fiber knob or downstream of the second turn (Turn b) of any shaft repeat, the remaining shaft repeats having been removed.
  • the new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
  • Type B similar to type A but with a linker motif introduced immediately upstream of the trimerisation signal .
  • Type C where the trimerisation motif is introduced after the first shaft repeat and in turn followed the shaft repeats 17 through 21.
  • the new cellbinding ligand is introduced downstream of the trimerisation signal with an amino acid linker motif being added between the trimerisation signal and the cellbinding ligand.
  • Type D where the cellbinding ligand is introduced between the restriction sites Nhel and Hpal in the fiber shaft, with an amino acid linker being added both upstream and downstream of the ligand.
  • Type D/ ⁇ where the cellbinding ligand is introduced between the restriction sites Nhel and Hpal in the fiber shaft, with an amino acid linker being added both upstream and downstream of the ligand.
  • Type D This is a variant of Type D where the fiber shaft downstream of the cellbinding ligand in Type D was removed.
  • Type D and (D/ ⁇ ) are constructed with the normal knob and with the knob being replaced with an external trimerisation signal as in Types A and B.
  • Type E which are similar to Type A but with part of the knob being retained immediately upstream of the external trimerisation motif.
  • Recombinant fibers are cloned into Baculovirus and expressed in Sf9 cells and/or cloned into the vector pSecTag and expressed in COS cells as secreted proteins. Expression is monitored by immunostaining with monoclonal antibodies 4D2.5 (anti Ad5 fiber) and 2A6.36 (anti trimerised Ad5 fiber) . Expression and trimerisation is obvious in all recombinant fibers irrespective of length and trimerisation motif.
  • 4D2 antibody against fiber a-EGF: antibody against epidermal growth factor a-Id: anti idiotypic antibody specific for G250 a-Ig: antibody against mouse immunoglobulin
  • CH2 immunoglobulin heavy chain constant domain 2
  • EGF epidermal growth factor
  • G250 monoclonal antibody specific for renal carcinoma
  • H heavy chain variable sequence from G250 (SEQ ID NO:
  • IgG3 amino acid linker derived from hinge region of human IgG3 , SEQ ID NO: 7
  • RGD The amino acid sequence arginine-glycine-aspartic acid
  • Nuclear localization is assessed by immunostaining of fibers in Sf9 cells 24 hours after infection with the relevant Baculovirus clone. Some results are shown in Table 2 below. It is clear from these experiments that some recombinant fibers show a grossly impaired nuclear localization in Sf9 cells despite the presence of the nuclear addressing signal in the fiber tail.
  • Recombinant and native fibers have also been expressed in COS cells, targeted for expression in the cytosol after cloning into the vector pcDNA 3.1.
  • the fibers would be detected in the nucleus, due to the presence of the native nuclear localization signal in the fiber tail.
  • nuclear localization has so far only been detected in the wild type fiber and in fibers with single-chain T-cell receptors, i.e. the fibers which have produced the most efficient virus (se below) .
  • NLS nuclear localization signal
  • SEQ ID NO: 9 the amino acid sequence SEQ ID NO: 9 (Fisher-Fantuzzi L and Vesco C: Cell -Dependent Efficiency of Reiterated Nuclear Signals in a Mutant Simian Virus 40 Oncoprotein Targeted to the Nucleus. Mol Cell Biol , 8:5495-5503, 1988).
  • the external NLS sequence is added immediately up-stream of the RGD motif. It is found that the presence of the external NLS dramatically improved the nuclear localization in the cases where it has been investigated. In fact, as mentioned above the fiber constructs lacking the external NLS were undetectable in the transfected cells (Table 3) .
  • the wild type fiber in the Ad genome is exchanged for recombinant fibers by the following method (see Fig 3) .
  • the plasmid pTG3602 (Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A and Mehtali M: Efficient generation of Recombinant Adenovirus Vectors by Homologous Recombination i Escherichia Coli, J Virol , 70: 4805-4810, 1996) containing the entire Ad5 genome as a Pacl-Pacl fragment is used as starting material.
  • the 3 kb fiber shuttle with recombinant fiber is re- introduced into the 9 kb fragment cut with Nhel using homologous recombination in E.coli (see ref. in previous passage) .
  • the resulting recombinant 9 kb fragment is finally excised from the vector with Spel and Pacl and joined to the isolated 27 kb fragment by Cosmid cloning.
  • Cosmid clones are also restricted with Hind III and the presence of restriction fragments of the expected size verified on gels.
  • Recombinant Ad genomes are isolated after restriction with Pac 1 and used to transfect suitable cells. The occurrence of plaques is determined by microscopic inspection of the transfected cell cultures.
  • Supernatants are harvested from primarily transfected cultures and used to infect secondary cultures. The occurrence of cytopathogenic effects and plaques are monitored by microscopy.
  • the present invention describes methods whereby knobless, trimerisation-competent fibers with new cellbinding ligands can been created and rescued into virus and have identified locations within the fiber-shaft which tolerates inserts of foreign ligands.
  • the importance of intracellular trafficking of recombinant fibers has also been identified.
  • Recombinant virus made using the invented technology should be highly useful in human medicine. Virtually unlimited opportunities for targeted gene-therapy may be developed by the combination of the technology described here and the identification of cell- binding ligands by phage-display.
  • Ad made re-targeted by the present invention
  • tumor diseases the following options exist:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un adénovirus recombinant de tropisme modifié. Dans un adénovirus, la fibre pentone native composée d'une queue, d'une tige et d'un spicule incluant un motif de trimérisation, a été changée en ce sens que le spicule natif contenant la structure liaison de cellule et le motif de trimérisation natif ont été enlevés et un nouveau ligand liaison de cellule et un motif de trimérisation externe ont été introduits dans la fibre virus. L'invention concerne également l'adénovirus recombinant destiné au traitement de maladies de l'être humain, in vivo ou par des procédés in vitro, ainsi qu'un procédé de sauvetage de fibres adénovirus recombinant dans le génome adénovirus.
PCT/SE2000/001390 1999-07-06 2000-06-30 Adenovirus recombinant Ceased WO2001002431A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002378324A CA2378324A1 (fr) 1999-07-06 2000-06-30 Adenovirus recombinant
EP00946680A EP1196435A1 (fr) 1999-07-06 2000-06-30 Adenovirus recombinant
AU60401/00A AU763733B2 (en) 1999-07-06 2000-06-30 Recombinant adenovirus
KR1020027000132A KR20020092886A (ko) 1999-07-06 2000-06-30 재조합 아데노바이러스
JP2001508218A JP2003531568A (ja) 1999-07-06 2000-06-30 組換え型アデノウイルス

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902601A SE9902601D0 (sv) 1999-07-06 1999-07-06 Recombinant adenovirus
SE9902601-5 1999-07-06
US14363299P 1999-07-14 1999-07-14
US60/143,632 1999-07-14

Publications (1)

Publication Number Publication Date
WO2001002431A1 true WO2001002431A1 (fr) 2001-01-11

Family

ID=26663617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001390 Ceased WO2001002431A1 (fr) 1999-07-06 2000-06-30 Adenovirus recombinant

Country Status (7)

Country Link
EP (1) EP1196435A1 (fr)
JP (1) JP2003531568A (fr)
KR (1) KR20020092886A (fr)
CN (1) CN1359391A (fr)
AU (1) AU763733B2 (fr)
CA (1) CA2378324A1 (fr)
WO (1) WO2001002431A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008263A3 (fr) * 2000-07-19 2002-06-13 Got A Gene Ab Virus modifie
WO2001081607A3 (fr) * 2000-04-26 2002-06-13 Crucell Holland Bv Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations
WO2002063010A3 (fr) * 2001-02-07 2003-11-27 Wilex Ag Procede pour produire des anticorps recombines
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
WO2007094663A1 (fr) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Particules adénovirales ayant une protéine s adénovirale chimérique, leur utilisation, et procédés de production de ces particules
EP2248903A1 (fr) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
CN102775500A (zh) * 2012-08-03 2012-11-14 郑骏年 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
US8828381B2 (en) 2002-07-01 2014-09-09 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
US9605075B2 (en) 2001-02-07 2017-03-28 Wilex Ag Hybridoma cell line G250 and its use for producing monoclonal antibodies
US11077156B2 (en) 2013-03-14 2021-08-03 Salk Institute For Biological Studies Oncolytic adenovirus compositions
US11130968B2 (en) 2016-02-23 2021-09-28 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11401529B2 (en) 2016-02-23 2022-08-02 Salk Institute For Biological Studies Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics
US11813337B2 (en) 2016-12-12 2023-11-14 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US12365878B2 (en) 2018-04-09 2025-07-22 Salk Institute For Biological Studies Oncolytic adenovirus with enhanced replication properties comprising modifications in E1A, E3, and E4
US12514887B2 (en) 2014-09-24 2026-01-06 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005310604A1 (en) * 2004-11-30 2006-06-08 Kiim Pharm Lab. Inc. Anti-HIV drug, polypeptide constituting the same, gene encoding the polypeptide and method of producing the anti-HIV drug
CN104634978A (zh) * 2013-11-13 2015-05-20 长春百克生物科技股份公司 一种分型检测腺病毒中和抗体的方法以及用于分型检测腺病毒中和抗体的试剂盒
CN107683289B (zh) * 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026281A1 (fr) * 1995-02-21 1996-08-29 Genvec, Inc. Proteine fibreuse chimere d'adenovirus et ses procedes d'utilisation
WO1997020051A2 (fr) * 1995-11-28 1997-06-05 Genvec, Inc. Vecteurs et procedes permettant de transferer des genes dans des cellules
WO1997020575A1 (fr) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Vecteurs adenoviraux cibles
WO1999041359A1 (fr) * 1998-02-17 1999-08-19 The Uab Research Foundation Adenovirus modifie contenant une proteine fibrillaire de substitution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026281A1 (fr) * 1995-02-21 1996-08-29 Genvec, Inc. Proteine fibreuse chimere d'adenovirus et ses procedes d'utilisation
WO1997020051A2 (fr) * 1995-11-28 1997-06-05 Genvec, Inc. Vecteurs et procedes permettant de transferer des genes dans des cellules
WO1997020575A1 (fr) * 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Vecteurs adenoviraux cibles
WO1999041359A1 (fr) * 1998-02-17 1999-08-19 The Uab Research Foundation Adenovirus modifie contenant une proteine fibrillaire de substitution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUSAN C. STEVENSON ET AL.: "Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein", JOURNAL OF VIROLOGY, vol. 71, no. 6, June 1997 (1997-06-01), pages 4782 - 4790, XP002933603 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081607A3 (fr) * 2000-04-26 2002-06-13 Crucell Holland Bv Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations
US6849446B2 (en) 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
WO2002008263A3 (fr) * 2000-07-19 2002-06-13 Got A Gene Ab Virus modifie
US7456008B2 (en) 2000-07-19 2008-11-25 Got-A-Gene Ab Modified virus comprising one or more non-native polypeptides
WO2002063010A3 (fr) * 2001-02-07 2003-11-27 Wilex Ag Procede pour produire des anticorps recombines
US9605075B2 (en) 2001-02-07 2017-03-28 Wilex Ag Hybridoma cell line G250 and its use for producing monoclonal antibodies
US8828381B2 (en) 2002-07-01 2014-09-09 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
WO2007094653A1 (fr) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Particules adénovirales ayant une protéine s adénovirale chimérique, et utilisation et procédés de production de ces particules
WO2007094663A1 (fr) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Particules adénovirales ayant une protéine s adénovirale chimérique, leur utilisation, et procédés de production de ces particules
EP2695945A1 (fr) 2009-04-29 2014-02-12 Universitat Autònoma De Barcelona Procédés et réactifs pour le transfert génétique efficace et ciblé vers des cellules de lignage monocyte-macrophage
EP2248903A1 (fr) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
CN102775500A (zh) * 2012-08-03 2012-11-14 郑骏年 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
US11077156B2 (en) 2013-03-14 2021-08-03 Salk Institute For Biological Studies Oncolytic adenovirus compositions
US12589128B2 (en) 2013-03-14 2026-03-31 Salk Institute For Biological Studies Oncolytic adenovirus compositions
US12514887B2 (en) 2014-09-24 2026-01-06 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use
US11130968B2 (en) 2016-02-23 2021-09-28 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11401529B2 (en) 2016-02-23 2022-08-02 Salk Institute For Biological Studies Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics
US12281324B2 (en) 2016-02-23 2025-04-22 Salk Institute For Biological Studies Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics
US11813337B2 (en) 2016-12-12 2023-11-14 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US12365878B2 (en) 2018-04-09 2025-07-22 Salk Institute For Biological Studies Oncolytic adenovirus with enhanced replication properties comprising modifications in E1A, E3, and E4

Also Published As

Publication number Publication date
KR20020092886A (ko) 2002-12-12
CA2378324A1 (fr) 2001-01-11
AU763733B2 (en) 2003-07-31
AU6040100A (en) 2001-01-22
JP2003531568A (ja) 2003-10-28
CN1359391A (zh) 2002-07-17
EP1196435A1 (fr) 2002-04-17

Similar Documents

Publication Publication Date Title
AU763733B2 (en) Recombinant adenovirus
ES2246533T3 (es) Fibra adenovirica modificada y adenovirus dianas.
CA2213343C (fr) Proteine fibreuse chimere d'adenovirus et ses procedes d'utilisation
Krasnykh et al. Genetic targeting of adenoviral vectors
AU734515B2 (en) A short-shafted adenoviral fiber and its use
US20080286292A1 (en) Molecular vaccine linking intercellular spreading protein to an antigen
US7456008B2 (en) Modified virus comprising one or more non-native polypeptides
JP2003508057A (ja) 改変アデノウイルスファイバーおよび用途
JP4683682B2 (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクター
AU2004238979B2 (en) Broadening adenovirus tropism
Ambriović-Ristov et al. Shortening adenovirus type 5 fiber shaft decreases the efficiency of postbinding steps in CAR-expressing and nonexpressing cells
US6815200B1 (en) Modified adenovirus containing a fiber replacement protein
CA2256696C (fr) Petits virus a arn modifies
US20050003548A1 (en) Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
WO2001092299A9 (fr) Particules d'adenovirus avec proteines de fibres mutagenisees
US20020137213A1 (en) Adenovirus particles with mutagenized fiber proteins
JP2003514577A (ja) 改変アデノウイルス繊維および使用
AU723006B2 (en) Modified small RNA viruses
WO2004011489A2 (fr) Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes
Richards Identification and functional characterization of novel receptor ligands of CD40 and alpha (v) beta (3) integrin: Implications for gene delivery
Medina-Kauwe A Novel Gene Delivery System Targeted to fireast Cancer Cells
Mikheeva et al. Genetic Targeting of an Adenovirus Vector
Van Kessel Characterization of the IIIa protein of porcine adenovirus type 3
Mahasreshti et al. Identification of Sites in Adenovirus Hexon
Miller Modification of the viral and cellular requirements for adenovirus entry into cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809885.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2378324

Country of ref document: CA

Ref document number: 60401/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020027000132

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000946680

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000946680

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027000132

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 60401/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000946680

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020027000132

Country of ref document: KR